Back to top

Analyst Blog

Corcept Therapeutics Inc. (CORT - Snapshot Report) recently announced that it has formed a partnership with Idis.

As per the partnership, Corcept’s Korlym will be available to patients outside the U.S. through a global program, Idis Access Program. Korlym is approved in the U.S. as a once-daily oral medication for the treatment of hyperglycemia secondary to endogenous Cushing’s syndrome in adults who have type II diabetes or glucose intolerance and cannot undergo a surgery.

We note that Korlym was launched by Corcept in the U.S. in Apr 2012. The U.S. Food and Drug Administration (FDA) approved the drug in Feb 2012.

The program enables patients to obtain access to investigational or approved drugs before the drugs are commercially launched in their country. The access is obtained through a regulatory-compliant and ethical channel on a named-patient basis.

We note that Corcept enjoys orphan drug designation for Korlym from the FDA for the approved indication. The European Commission also granted orphan drug designation to Korlym for the treatment of endogenous Cushing’s syndrome in Oct 2011.

We note that Korlym is the only approved drug at Corcept. Hence the successful commercialization of Korlym continues to be a priority for Corcept. Corcept’s partnership with Idis will allow physicians to prescribe Korlym outside the U.S. as well.

We remind investors that Corcept also has an ongoing phase III study on mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression.

Corcept currently carries a Zacks Rank #3 (Hold). Right now, stocks like Jazz Pharmaceuticals (JAZZ - Analyst Report), Actelion Ltd. (ALIOF) and WuXi PharmaTech (Cayman) Inc. (WX - Snapshot Report) look attractive. All three carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
PANTRY INC PTRY 21.02 +2.09%
INTEL CORP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%